About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event November 11, 2023 6:00 PM ET Company Participants Daniel Bohsen - Head of Investor Relations Martin Holst Lange - Executive Vice President, Development Robin Evers - Senior Vice President of Medical Affairs, Regulatory and Safety Conference Call Participants Richard Vosser - JPMorgan Chase & Co Emily Field - Barclays Michael Novod - Nordea Pete Verdult - Citi Seamus Fernandez - Guggenheim Securities Martin Parkhøi - SEB Pete Welford - Jefferies Michael ...

Novo Nordisk A/S (NVO) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Daniel Bohsen - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President, Commercial Strategy and Corporate Affairs Doug Langa - Executive Vice President, North America Operations Martin Holst Lange - Executive Vice President, Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Ca ...

1 Investor presentation First six months of 2023 RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk –a focused healthcare company Investor presentation First six months of 2023 2 Novo Nordisk® Investor presentation First six months of 2023 Agenda Progress on Strategic Aspirations 2025 Commercial execution Agenda Innovation and therapeutic focus Financials 3 Novo Nordisk® Investor presentation First six months of 2023 Forward-looking statements Novo Nordisk's reports filed with or furnished to the ...

Novo Nordisk A/S (NVO) Q2 2023 Earnings Conference Call August 10, 2023 7:00 AM ET Company Participants Daniel Bohsen - CVP & Head, IR Lars Jorgensen - President & CEO Camilla Sylvest - EVP, Commercial Strategy & Corporate Affairs Douglas Langa - EVP, North America Operations Martin Lange - EVP, Development Karsten Knudsen - EVP & CFO Conference Call Participants Martin Parkhoi - SEB Richard Parkes - BNP Paribas Exane Emily Field - Barclays Bank Peter Verdult - Citigroup Harry Sephton - Crédit Suisse Peter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 3, 2023 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 6-K _________________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 1, 2023 _________________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) _________________________ Novo Allé DK-2880 Bagsværd Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ _________________________ _________________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 February 2, 2022 NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) | --- | |---------------------------| | | | | | | | | | _________________________ | | | | | | | | | | | | | | | | | | | (Adress of principal executive offices ...